Systemic sclerosis is a rare autoimmune connective tissue disease characterized by skin thickening, fibrosis, and involvement of internal organs and vasculature. Clinical manifestations vary from limited cutaneous disease to diffuse multisystem involvement.
AbbVie reported positive Phase 3 data for Skyrizi's subcutaneous Crohn's disease treatment and is advancing lutikizumab and Rinvoq in hidradenitis suppurativa, with multiple readouts expected throughout 2026 as the company pursues combination therapy strategies.
A 24-year-old woman with refractory lupus achieved two successful pregnancies following dual-target CAR-T cell therapy, while bispecific T cell engagers showed efficacy in treatment-refractory antisynthetase syndrome and systemic sclerosis patients.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07596680 |
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07558850 |
Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases |
RECRUITING | NA |
| NCT07515638 |
Immun4Cure Cohort of Autoimmune Diseases |
NOT_YET_RECRUITING | |
| NCT07497087 |
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis |
NOT_YET_RECRUITING | PHASE3 |
| NCT07402863 |
Self-Guided Resilience-Building Energy Management to Enhance Well-being (RENEW) Intervention for People With Systemic Sclerosis (SSc) |
COMPLETED | NA |
| NCT07335562 |
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis |
RECRUITING | PHASE3 |
| NCT07295847 |
A Study of AZD0120 in Autoimmune Diseases |
RECRUITING | PHASE1 |
| NCT07284797 |
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases |
RECRUITING | PHASE1 |
| NCT07246096 |
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases |
RECRUITING | EARLY_PHASE1 |
| NCT07236801 |
Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases |
RECRUITING | PHASE1 |
